Murphy Analytics Announces Initiation of Coverage on Axxess Pharma Inc.

St. Louis, Missouri - November 5, 2013.  Murphy Analytics (MA) has initiated coverage on Axxess Pharma Inc. (PinkSheets: AXXE). The Initiation Report contains a detailed discussion of AXXE's planned business operations, market dynamics, financials, potential cash flows, and risks. The Initiation Report is available at: http://www.murphyanalytics.com/uploads/AXXE_Initiation.pdf.

Axxess is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. Axxess's goal is to bring additional products to the market and provide new, innovative options for better health spanning areas such as high cholesterol, blood pressure, acute pain, to optimal health management through improved nutritional supplements. Analyst Patrick Murphy notes in the report:  "...with a recently announced line of credit term sheet, AXXE is demonstrating further progress in developing a model to capitalize on highly attractive market opportunities."

About Murphy Analytics

Murphy Analytics is an investment research firm providing coverage of microcap stocks. Utilizing institutional caliber, fundamental analysis, Murphy Analytics helps readers become more informed about equities without extensive analyst coverage. Murphy Analytics LLC is owned by Patrick J. Murphy, who has nearly 20 years of capital markets experience, providing institutional investment and transaction analysis across a range of asset classes including microcap equities, commercial real estate debt and equity, municipal derivatives and public finance, venture capital, fixed income, CMBS and mortgage REIT's. 

Contact:
Patrick J. Murphy, CFA
[e-mail]

Disclosure:  MA was paid $5,000 by the Company in advance of the publication of this report. Neither MA nor the analyst owns or trades the shares of covered companies.  Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. MA provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.  This report is neither a solicitation to buy nor an offer to sell securities and is to be used for informational purposes only and should not be used as basis for investment decisions. MA is not an investment advisor or broker/dealer and this report does not provide investment
advice.